On January 24, 2022, LAMH passed the audit of Zhongguancun High-Tech Committee and received the certificate of “Zhongguancun High-Tech Enterprise” issued by Zhongguancun Science and Technology Park Management Committee. This certification marks the recognition of LAMH’s innovative technology capability in the field of artificial intelligence-driven healthcare and its ability to transform technological achievements, which reflects LAMH’s strong technological research and development capability and market competitiveness in the field of early tumor screening.
The “Zhongguancun High-tech Enterprise” refers to the high-tech field supported by the state in Zhongguancun Science and Technology Park, through continuous research and development and transformation of technological achievements, thus forming the core independent intellectual property rights of the enterprise, and based on this to carry out business activities, the major high-tech achievements into productivity, belonging to the domestic or international Advanced enterprises. In addition, high-tech enterprises are special qualifications established by the state to support and encourage the development of high-tech enterprises and enhance the competitiveness of the national economy, and occupy an important strategic position in China’s economic development.
According to the declaration regulations, the core indexes such as the ratio of R&D investment, the ratio of high-tech product revenue, the number of scientific researchers, and the technical innovation capacity are satisfied before the enterprise is qualified to obtain this certification. The qualification of high-tech enterprise in Zhongguancun is not only an honor, but also a responsibility, and a high recognition of its R&D team, innovative technology, intellectual property rights, product development and market competitiveness.
LAMH is founded by international business leaders, top scientists and authoritative doctors with the concept of “making cancer screening more accurate, earlier and easier”, and has raised more than RMB 1 billion since its establishment, cooperated with many top cancer centers, universities and their affiliated hospitals in China and the United States, and has been published in Nature, Science, Cell and PNAS. LAMH has published relevant research results in top international journals such as Nature, Science, Cell, PNAS and subjournals, and established a full product pipeline for early screening and diagnosis of liver cancer, intestinal cancer, lung cancer and pan-cancer types.
LAMH has the world’s earliest methylation technology accumulation and integration with a large number of clinical samples validation data, exclusive AI algorithm patent and achievable clinical reporting strong combination, its core technology focus on cancer early screening research, through the detection of specific ctDNA methylation changes in the blood for cancer early screening and auxiliary diagnosis, and completed ctDNA methylation test for liver cancer diagnosis, and the whole cycle of liver cancer monitoring. and full cycle monitoring of liver cancer.
KAMBECAN®, the early and precise screening product for liver cancer launched by LAMH, has a product sensitivity of 92.5% and specificity of 97.5%. At the same time, LAMH has focused on laying out channels such as hospitals, health management centers, pharmacies and online e-commerce to reach urban people with high risk of liver cancer; it has also established joint laboratories with several hospitals to promote the rapid in-hospital implementation of liver cancer early screening, and cooperated with China Anti-Cancer Association, National Cancer Center, pharmaceutical companies and pharmacies to improve the prevalence of liver cancer early screening. It is reported that LAMH will receive the first Class III IVD certificate for liver cancer methylation from the State Drug Administration in 1 quarter of 2022.
Mr. Zeyue Zhang, Chairman and CEO of LAMH, said that there is great value and significance in addressing the low penetration rate of liver cancer screening in China, which accounts for half of the global incidence and deaths of liver cancer, and the high risk factors for liver cancer are very dominant, including hepatitis B, hepatitis C, cirrhosis and family history of liver cancer, and there are more than 100 million people in this category, and most of them are detected at a late stage, resulting in a median The majority of these people are found at an advanced stage, resulting in a very short median survival period. Since our founding in 2010, we have been strategically focused on technology and insisted on methylation as the basis for research and development. From 2020 to 2021, we have seen that early cancer screening is more accepted by the government, medical professionals, medical check-ups and the general public; then, 2022 is bound to be a year of compliance and commercialization promotion, and there are many things for us to do, not only how to open the professional channels for commercialization, but also to work with more enterprises to raise the awareness of residents’ health management and effectively improve The health level of the residents.